Antiresorptive treatments for corticosteroid-induced osteoporosis: a Bayesian network meta-analysis.

IF 5.2 2区医学 Q1 Medicine British medical bulletin Pub Date : 2022-09-22 DOI:10.1093/bmb/ldac017

Filippo Migliorini, Giorgia Colarossi, Jörg Eschweiler, Francesco Oliva, Arne Driessen, Nicola Maffulli

{"title":"Antiresorptive treatments for corticosteroid-induced osteoporosis: a Bayesian network meta-analysis.","authors":"Filippo Migliorini, Giorgia Colarossi, Jörg Eschweiler, Francesco Oliva, Arne Driessen, Nicola Maffulli","doi":"10.1093/bmb/ldac017","DOIUrl":null,"url":null,"abstract":"Introduction: Corticosteroid-induced osteoporosis (CIO) is the most common type of secondary osteoporosis, leading to fractures, and increased morbidity and mortality.Source of data: Pubmed, EMBASE, Scopus and Google Scholar databases.Areas of agreement: Prolonged glucocorticoids administration leads to secondary osteoporosis.Areas of controversy: The optimal management for CIO is controversial.Growing points: The present study compared bone mineral density, fractures and adverse events in patients undergoing treatment with risedronate, alendronate, zoledronate, denosumab or etidronate for CIO.Areas timely for developing research: For selected patients with CIO, alendronate performed better overall. These results must be interpreted within the limitations of the present study.Level of evidence: I, Bayesian network meta-analysis of randomized clinical trials.","PeriodicalId":9280,"journal":{"name":"British medical bulletin","volume":"100 1","pages":"46-56"},"PeriodicalIF":5.2000,"publicationDate":"2022-09-22","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9494254/pdf/","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"British medical bulletin","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1093/bmb/ldac017","RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"Medicine","Score":null,"Total":0}

引用次数: 0

Abstract

Introduction: Corticosteroid-induced osteoporosis (CIO) is the most common type of secondary osteoporosis, leading to fractures, and increased morbidity and mortality.

Source of data: Pubmed, EMBASE, Scopus and Google Scholar databases.

Areas of agreement: Prolonged glucocorticoids administration leads to secondary osteoporosis.

Areas of controversy: The optimal management for CIO is controversial.

Growing points: The present study compared bone mineral density, fractures and adverse events in patients undergoing treatment with risedronate, alendronate, zoledronate, denosumab or etidronate for CIO.

Areas timely for developing research: For selected patients with CIO, alendronate performed better overall. These results must be interpreted within the limitations of the present study.

Level of evidence: I, Bayesian network meta-analysis of randomized clinical trials.

Abstract Image

查看原文

微信好友朋友圈 QQ好友复制链接

本刊更多论文

抗吸收治疗皮质类固醇所致骨质疏松症：贝叶斯网络荟萃分析。

皮质类固醇诱导的骨质疏松症（CIO）是最常见的继发性骨质疏松症，可导致骨折，发病率和死亡率增加。数据来源：Pubmed， EMBASE， Scopus和谷歌Scholar数据库。同意领域：长期使用糖皮质激素导致继发性骨质疏松症。争议领域：CIO的最佳管理是有争议的。要点：本研究比较了接受利塞膦酸盐、阿仑膦酸盐、唑来膦酸盐、地诺单抗或地替膦酸盐治疗CIO患者的骨密度、骨折和不良事件。及时开展研究的领域：对于选定的CIO患者，阿仑膦酸钠的总体疗效更好。这些结果必须在本研究的限制范围内加以解释。证据水平：1，随机临床试验的贝叶斯网络meta分析。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文去求助

来源期刊

British medical bulletin 医学-医学：内科

CiteScore

13.10

自引率

1.50%

发文量

审稿时长

>12 weeks

期刊介绍： British Medical Bulletin is a multidisciplinary publication, which comprises high quality reviews aimed at generalist physicians, junior doctors, and medical students in both developed and developing countries. Its key aims are to provide interpretations of growing points in medicine by trusted experts in the field, and to assist practitioners in incorporating not just evidence but new conceptual ways of thinking into their practice.